Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.

@article{Yamamoto2011OralAC,
  title={Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.},
  author={Suguru Yamamoto and Yiqin Zuo and Ji Ma and Patricia G. Yancey and Tracy Earl Hunley and Masaru Motojima and Agnes B. Fogo and Macrae F Linton and Sergio Fazio and Iekuni Ichikawa and Valentina Kon},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2011},
  volume={26 8},
  pages={2491-7}
}
BACKGROUND Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis… CONTINUE READING